Find therapies in clinical trials near you – page 118

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Phase 3 Study of Enfortumab Vedotin plus Pembrolizumab in Adults with Muscle‑Invasive Bladder Cancer Ineligible for Cystectomy

Phase 3 Study of Enfortumab Vedotin plus Pembrolizumab in Adults with Muscle‑Invasive Bladder Cancer Ineligible for Cystectomy

Safety and Efficacy of MK-1045 with Tocilizumab in Patients with CLL/SLL

Safety and Efficacy of MK-1045 with Tocilizumab in Patients with CLL/SLL

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Evaluation of Long-Term Efficacy and Safety of Tirzepatide Versus Intensified Conventional Care in Early Treatment of Type 2 Diabetes in Adults

Evaluation of Long-Term Efficacy and Safety of Tirzepatide Versus Intensified Conventional Care in Early Treatment of Type 2 Diabetes in Adults

Semaglutide for reducing visceral fat in adults with HIV, BMI 25–30 kg/m2 and no diabetes: randomized trial with lifestyle intervention

Semaglutide for reducing visceral fat in adults with HIV, BMI 25–30 kg/m2 and no diabetes: randomized trial with lifestyle intervention

Safety and Efficacy of Efimosfermin Alfa vs Placebo in Adults with Alcohol-Related Liver Disease

Phase 3 Study of Pridopidine Hydrochloride for Safety and Efficacy in Adults with Huntington’s Disease

Phase 3 Study of Pridopidine Hydrochloride for Safety and Efficacy in Adults with Huntington’s Disease

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer